ICG140:CD19-CD123 cCAR T-cells

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameICG140:CD19-CD123 cCAR T-cells

Drug Alias Namedual anti-CD19/anti-CD123 CAR T-cell therapy (iCell Gene Therapeutics)

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsInterleukin-3 receptor subunit alpha modulators

TargetsInterleukin-3 receptor subunit alphaB-lymphocyte antigen CD19

Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesiCell Gene Therapeutics LLC

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesiCell Gene Therapeutics LLC

Active IndicationsN/A

Inactive IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A